Cost-efficacy in interventional cardiology; results from the EPISTENT study
| Autor: | B A van Hout, J.E.F. Zwart-van Rijkom |
|---|---|
| Přispěvatelé: | Population-based studies of drug treatment: from molecule to patient outcomes, Universiteit Utrecht, Dep Farmaceutische wetenschappen |
| Rok vydání: | 2001 |
| Předmět: |
medicine.medical_specialty
Epidemiology medicine.medical_treatment Combined use Biomedische technologie en medicijnen Revascularization Farmacie/Biofarmaceutische wetenschappen (FARM) Internal medicine Abciximab Medicine Combined Modality Therapy cardiovascular diseases health care economics and organizations Ziekenhuisstructuur en organisatie van de gezondheidszorg Interventional cardiology business.industry Farmacie(FARM) Stent Health economy Cost efficacy Surgery Cardiology Public Health Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | European Heart Journal. 22:1476-1484 |
| ISSN: | 0195-668X |
| Popis: | Aims The EPISTENT study has demonstrated that the combined use of abciximab and stenting as an adjunct to PTCA leads to increased event-free survival compared to either using abciximab or stenting alone. However, this combined strategy may be costly and the additional costs have to be weighted against the additional effects. Method and Results The 6-months efficacy data from the EPISTENT study are combined with Dutch estimates of unit costs. Adding a stent to a procedure with abciximab further decreases the number of revascularizations at an extra cost of Euros12000 (95% upper limit (u.l.) Euros31000) per additional major adverse cardiac event-free survivor. Adding abciximab to a stenting procedure decreases the incidence of myocardial infarctions at an extra cost of Euros13000 (95% u.l. Euros27000) per additional myocardial infarction-free survivor. In the subgroup of diabetics, adding abciximab improves revascularization rates as well, resulting in a cost-efficacy rate of Euros2000 (95% u.l. Euros25000) per additional MACE-free survivor, with uncertainty regions indicating potential costs savings. Conclusion The combination of stenting and abciximab costs about Euros13000 to avoid one event after PTCA. In diabetic patients the strategy may be cost-saving. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|